title: Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.
abstract: CLL is extremely heterogeneous in its clinical course, with some patients living decades with no need for treatment whilst others have a rapidly aggressive clinical course. A major focus of research has been to try to identify those biological factors that influence this heterogeneity. The goal of therapy has been to maintain the best quality of life and treat only when patients become symptomatic from their disease. For the majority of patients this means following a "watch and wait" approach to determine the rate of progression of the disease and assess for development of symptoms. Any alteration to this approach will require identification of criteria that define patients sufficiently "high-risk" that they gain benefit by introduction of early therapy. The use of molecular profiling to suggest particular therapies is currently appropriate only in defining the treatment of the minority of patients with 17p deletions or p53 mutations and in all other circumstances remains a clinical trial question.
authors.affiliation: Medical Oncology, Institute of Cancer, Barts and London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom. t.butler@qmul.ac.uk
authors.forename: Tom
authors.initials: T
authors.lastname: Butler
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
mesh_terms: D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D017384:Sequence Deletion; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
references.citation: J Exp Med. 2001 Dec 3;194(11):1625-38
references.pmid: 11733577
references.citation: Eur J Haematol. 2006 Apr;76(4):294-8
references.pmid: 16519700
references.citation: J Clin Oncol. 2005 Jun 10;23(17):3877-85
references.pmid: 15809452
references.citation: Blood. 2004 Jun 15;103(12):4389-95
references.pmid: 14962897
references.citation: Blood. 1993 Sep 15;82(6):1820-8
references.pmid: 8104532
references.citation: J Natl Cancer Inst. 1999 May 19;91(10):861-8
references.pmid: 10340906
references.citation: J Clin Oncol. 2005 May 1;23(13):2884-5
references.pmid: 15738532
references.citation: N Engl J Med. 2000 Dec 14;343(24):1750-7
references.pmid: 11114313
references.citation: N Engl J Med. 2009 Feb 12;360(7):659-67
references.pmid: 19213679
references.citation: Blood. 2006 Aug 1;108(3):853-61
references.pmid: 16601244
references.citation: Blood. 1999 Sep 15;94(6):1840-7
references.pmid: 10477712
references.citation: N Engl J Med. 1998 May 21;338(21):1506-14
references.pmid: 9593789
references.citation: Blood. 1996 Sep 15;88(6):2228-35
references.pmid: 8822943
references.citation: Blood. 1999 Mar 1;93(5):1732-7
references.pmid: 10029603
references.citation: N Engl J Med. 1999 Nov 11;341(20):1520-9
references.pmid: 10559454
references.citation: Blood. 2007 Jun 1;109(11):4679-85
references.pmid: 17299097
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: Blood. 2002 Feb 1;99(3):1023-9
references.pmid: 11807008
references.citation: Leuk Lymphoma. 2006 Jun;47(6):1053-61
references.pmid: 16840197
references.citation: Br J Haematol. 1986 Mar;62(3):567-75
references.pmid: 3954968
references.citation: Acta Haematol. 1989;81(4):181-5
references.pmid: 2502891
references.citation: J Clin Oncol. 2007 Mar 1;25(7):799-804
references.pmid: 17283363
references.citation: Blood. 2008 May 15;111(10):5101-8
references.pmid: 18326815
references.citation: Blood. 2002 Aug 15;100(4):1177-84
references.pmid: 12149195
references.citation: Cytometry B Clin Cytom. 2006 Jul 15;70(4):214-7
references.pmid: 16906580
references.citation: Blood. 2002 Mar 15;99(6):2262-4
references.pmid: 11877310
references.citation: Blood. 2003 Jun 15;101(12):4944-51
references.pmid: 12595313
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Am J Hematol. 1988 Nov;29(3):152-63
references.pmid: 3189311
references.citation: Blood. 2002 Aug 15;100(4):1410-6
references.pmid: 12149225
references.citation: Ann Oncol. 2000;11 Suppl 1:49-53
references.pmid: 10707779
references.citation: Blood. 2005 Jul 15;106(2):650-7
references.pmid: 15802535
references.citation: J Clin Oncol. 2006 Jan 20;24(3):437-43
references.pmid: 16344317
references.citation: Blood. 2008 Sep 1;112(5):1923-30
references.pmid: 18577710
references.citation: Leukemia. 2005 May;19(5):750-8
references.pmid: 15759031
references.citation: Blood. 2008 Dec 15;112(13):5122-9
references.pmid: 18812466
references.citation: Leukemia. 1994 Oct;8(10):1640-5
references.pmid: 7523797
references.citation: Haematologica. 2005 Mar;90(3):391-9
references.pmid: 15749671
references.citation: Blood. 1993 Dec 1;82(11):3452-9
references.pmid: 8241511
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
references.pmid: 12434020
references.citation: Semin Oncol. 2006 Apr;33(2):186-94
references.pmid: 16616065
references.citation: Haematologica. 2009 Sep;94(9):1259-65
references.pmid: 19734417
references.citation: Blood. 1992 Oct 15;80(8):2074-80
references.pmid: 1382719
references.citation: N Engl J Med. 2003 May 1;348(18):1764-75
references.pmid: 12724482
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):995-1004
references.pmid: 19188171
references.citation: J Clin Oncol. 2006 Feb 20;24(6):969-75
references.pmid: 16418492
references.citation: J Pathol. 2005 Mar;205(4):507-13
references.pmid: 15685592
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4079-88
references.pmid: 15767648
references.citation: Cancer. 1984 Dec 1;54(11):2450-5
references.pmid: 6498737
references.citation: Blood. 2005 Nov 1;106(9):3175-82
references.pmid: 16014569
references.citation: Blood. 2001 Jul 1;98(1):29-35
references.pmid: 11418459
references.citation: Lancet. 2007 Jul 21;370(9583):230-239
references.pmid: 17658394
references.citation: J Exp Med. 2001 Dec 3;194(11):1639-47
references.pmid: 11733578
references.citation: J Immunol. 2005 Mar 15;174(6):3749-56
references.pmid: 15749915
references.citation: Blood. 2003 Feb 1;101(3):1087-93
references.pmid: 12393552
references.citation: Leukemia. 2004 Apr;18(4):756-62
references.pmid: 14961036
references.citation: N Engl J Med. 2004 Aug 26;351(9):893-901
references.pmid: 15329427
references.citation: J Clin Invest. 1998 Oct 15;102(8):1515-25
references.pmid: 9788964
references.citation: Cytometry B Clin Cytom. 2006 May;70(3):136-41
references.pmid: 16568475
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71
references.pmid: 18362358
references.citation: Br J Haematol. 2009 Mar;144(6):818-31
references.pmid: 19183194
references.citation: Blood. 1984 Sep;64(3):642-8
references.pmid: 6466871
references.citation: Leuk Lymphoma. 2004 Feb;45(2):221-8
references.pmid: 15101705
references.citation: Blood. 2007 Jan 1;109(1):259-70
references.pmid: 16985177
references.citation: Blood. 1999 Sep 15;94(6):1848-54
references.pmid: 10477713
references.citation: Blood. 2004 May 1;103(9):3278-81
references.pmid: 14726385
references.citation: Leukemia. 2007 Jan;21(1):1-3
references.pmid: 17167526
references.citation: N Engl J Med. 2002 Aug 8;347(6):452-3
references.pmid: 12167696